210 related articles for article (PubMed ID: 22422332)
1. Determination of rivaroxaban in human plasma samples.
Harenberg J; Erdle S; Marx S; Krämer R
Semin Thromb Hemost; 2012 Mar; 38(2):178-84. PubMed ID: 22422332
[TBL] [Abstract][Full Text] [Related]
2. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
3. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
5. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
[TBL] [Abstract][Full Text] [Related]
6. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
7. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need.
Harenberg J; Marx S; Erdle S; Krämer R
Expert Rev Hematol; 2012 Feb; 5(1):107-13. PubMed ID: 22272710
[TBL] [Abstract][Full Text] [Related]
8. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
9. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
[TBL] [Abstract][Full Text] [Related]
12. Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.
Tichelaar V; de Jong H; Nijland H; Kluin-Nelemans H; Meijer K; Mulder A
Thromb Haemost; 2011 Nov; 106(5):990-2. PubMed ID: 21901233
[No Abstract] [Full Text] [Related]
13. Rivaroxaban: a new oral factor Xa inhibitor.
Perzborn E; Roehrig S; Straub A; Kubitza D; Mueck W; Laux V
Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):376-81. PubMed ID: 20139357
[TBL] [Abstract][Full Text] [Related]
14. Correlating prothrombin time with plasma rivaroxaban level.
Rodgers R; Bagot CN; Lawrence C; Hickman G; McGurk M; Tait RC
Br J Haematol; 2013 Dec; 163(5):685-7. PubMed ID: 24219334
[No Abstract] [Full Text] [Related]
15. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.
Harenberg J; Marx S; Krämer R; Giese C; Weiss C
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):637-41. PubMed ID: 21986465
[TBL] [Abstract][Full Text] [Related]
16. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
[TBL] [Abstract][Full Text] [Related]
17. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
18. Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.
Novak M; Schlagenhauf A; Bernhard H; Schweintzger S; Leschnik B; Muntean W
Blood Coagul Fibrinolysis; 2011 Oct; 22(7):588-92. PubMed ID: 21799400
[TBL] [Abstract][Full Text] [Related]
19. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.
Samama MM; Amiral J; Guinet C; Perzborn E; Depasse F
Thromb Haemost; 2010 Nov; 104(5):1078-9. PubMed ID: 20806114
[No Abstract] [Full Text] [Related]
20. The in-vitro anticoagulant effect of rivaroxaban in neonates.
Attard C; Monagle P; Kubitza D; Ignjatovic V
Blood Coagul Fibrinolysis; 2014 Apr; 25(3):237-40. PubMed ID: 24418940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]